Extended Data Fig. 2: Association between elevated IL-8 and survival across treatments and tumor types. | Nature Medicine

Extended Data Fig. 2: Association between elevated IL-8 and survival across treatments and tumor types.

From: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Extended Data Fig. 2

Percentage of patients with baseline serum IL-8 levels ≥23 pg/ml across Mel (CheckMate 067: nivolumab, n = 292; ipilimumab, n = 298; nivolumab plus ipilimumab, n = 297), RCC (CheckMate 025, n = 392), sqNSCLC (CheckMate 017, n = 108), and nsqNSCLC (CheckMate 057, n = 255) with nivolumab monotherapy, ipilimumab monotherapy, or nivolumab plus ipilimumab combination therapy, as indicated. PFS and OS hazard ratios (IL-8 ≥ 23 pg/ml versus IL-8 < 23 pg/mL) are also presented (95% CI). HR, hazard ratio; IL, interleukin; Mel, melanoma; nsqNSCLC, nonsquamous non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma; sqNSCLC, squamous NSCLC.

Back to article page